Insulet Corporation (PODD)

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.

Industry: Surgical & Medical Instruments & Apparatus (SIC 3841)

Market region: US

Address: 100 Nagog Park, Acton, MA, 01720

Market capitalization

10.38 billion USD (10,380,936,506 USD)

Listing date

05/15/2007

Weighted shares outstanding

69,354,199

Share class shares outstanding

69,354,199

https://www.insulet.com